To investigate treatment planning, delivery, tumor control, and toxicity of patients with benign intracranial tumors treated with HyperArc™, highlighting its significance compared to traditional methods.
Key Findings:
HyperArc™ demonstrated high geometric accuracy with a median registration offset of 0.32 mm, outperforming traditional methods.
Treatment plans achieved optimal local control with minimal toxicity, with specific rates of control and toxicity.
Automated planning with HyperArc™ allowed for efficient and precise delivery of radiation, reducing treatment time.
Interpretation:
The study indicates that HyperArc™ is a viable option for radiosurgery of benign intracranial tumors, providing effective tumor control while minimizing toxicity to surrounding healthy tissue, with implications for clinical practice.
Limitations:
Single-institution study may limit generalizability of results, and potential biases in patient selection.
Exclusion of grade III meningiomas may affect applicability to all benign tumor types, necessitating further research.
Conclusion:
HyperArc™ is effective for treating benign intracranial tumors, offering a promising alternative to traditional radiosurgery methods, but further research is needed to validate findings across multiple institutions.
by Whitney S. Hotsinpiller, Evan M. Thomas, Ian Tsekouras, Richard A. Popple, Markus Bredel, Christopher D. Willey, Barton L. Guthrie, James M. Markert, Kristen O. Riley, John B. Fiveash, Drexell Hunter Boggs
